# Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients

> **NCT02936414** · NA · COMPLETED · sponsor: **Tianjin Anding Hospital** · enrollment: 100 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Berberine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02936414
- **Lead sponsor:** Tianjin Anding Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-08
- **Final completion:** 2015-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2018-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02936414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02936414, "Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02936414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*